We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy


Accelerating AAV-Based Gene Therapy Development With MS


Accelerating AAV-Based Gene Therapy Development With MS

Who's speaking at this Webinar?

Matt Stone, PhD
Biologics Workflow Specialist SCIEX
Heather Mallory
Investigator GeneLeap Biotech (Luye Life Science)

Human embryonic kidney (HEK) 293 cells and Spodoptera frugiperda (Sf9) insect cells are commonly used to produce adeno-associated virus (AAV)-based gene therapeutics. However, they are likely to exhibit differences in post translational modifications (PTM) depending on the AAV capsid protein serotype which can impact safety and potency.

Here we explore differences shown in AAV serotype 8 produced in Sf9/baculovirus vs HEK293 cells. Using liquid chromatography mass spectrometry (LC-MS), the relative degrees of modification between proteins from the two expression systems were determined and their purity confirmed. Digestion followed by peptide mapping analysis then identified the exact sites and relative abundances of modified amino acids on the capsid proteins.

Using MS data to improve characterization of AAV from different sources will help scientists to make informed decisions in the development of cost-effective, safe and potent gene therapeutics.

By attending this webinar, you will learn:

-Why MS is valuable for AAV analysis

-What differences there are in the AAV produced in Sf9 vs HEK293 cells

-How MS can characterize these differences

-Where and how this information can be useful


Like what you just read? You can find similar content on the communities below.

Biopharma Cell Science Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free